Involvement of MM cell-derived exosomes in T lymphocytes immune responses. 2020

Qing Shao, and Ling Deng, and Hui Liu, and Zhaoyun Liu, and Jin Chen, and Fengjuan Jiang, and Siyang Yan, and Rong Fu
Department of Hematology, Tianjin Medical University General Hospital, Heping, Tianjin 300052, P.R. China.

Exosomes were reported to mediate cell communication in the tumor microenvironment; however, the effects of multiple myeloma (MM)-derived exosomes on the quantity and function of T cells remain unknown. Exosomes were extracted from MM cell lines (OPM2 and U266B1) by ultracentrifugation using a Total Exosome Isolation kit. Exosomes were co-cultured with CD4+ T, CD8+ T and regulatory T (Treg) cells that were isolated from healthy donors (HDs) and patients with MM using magnetic beads. Flow cytometry was used to detect T cells apoptosis and expression of perforin and granzyme B in CD8+ T cells. Cell viability was detected using Cell Counting kit-8, and interleukin 10 (IL-10) and transforming growth factor β (TGF-β) in cell supernatants were detected by ELISA. The apoptosis of HD-CD4+ T was higher in the OPM2 group, and viability in the U266B1 group was decreased. The apoptosis of HD-CD8+ T decreased in the OPM2 and U266B1 groups, and cell viability increased in the OPM2 and the U266B1 groups. Perforin of HD-CD8+ T in the U266B1 group was lower while perforin of MM-CD8+ T in OPM2 and U266B1 groups was markedly decreased. The apoptosis of HD-Treg was lower in the U266B1 group, but apoptosis of MM-Treg was higher in the U266B1 group. The viability of HD-Treg in U266B1 group increased but the viability of MM-Treg in OPM2 and U266B1 groups decreased. TGF-β from MM-Treg decreased in the OPM2 and U266B1 groups when compared with the control group (P<0.05). MM-derived exosomes promote apoptosis and inhibit proliferation of HD-CD4+ T, inhibit apoptosis and promote proliferation, but inhibit perforin of HD-CD8+ T, inhibit apoptosis and promote proliferation HD-Treg, and inhibit perforin of MM-CD8+ T and TGF-β secretion of MM-Treg.

UI MeSH Term Description Entries

Related Publications

Qing Shao, and Ling Deng, and Hui Liu, and Zhaoyun Liu, and Jin Chen, and Fengjuan Jiang, and Siyang Yan, and Rong Fu
March 1981, Transplantation proceedings,
Qing Shao, and Ling Deng, and Hui Liu, and Zhaoyun Liu, and Jin Chen, and Fengjuan Jiang, and Siyang Yan, and Rong Fu
January 2023, Frontiers in immunology,
Qing Shao, and Ling Deng, and Hui Liu, and Zhaoyun Liu, and Jin Chen, and Fengjuan Jiang, and Siyang Yan, and Rong Fu
January 1976, Advances in experimental medicine and biology,
Qing Shao, and Ling Deng, and Hui Liu, and Zhaoyun Liu, and Jin Chen, and Fengjuan Jiang, and Siyang Yan, and Rong Fu
January 2018, Cancer management and research,
Qing Shao, and Ling Deng, and Hui Liu, and Zhaoyun Liu, and Jin Chen, and Fengjuan Jiang, and Siyang Yan, and Rong Fu
January 2018, PloS one,
Qing Shao, and Ling Deng, and Hui Liu, and Zhaoyun Liu, and Jin Chen, and Fengjuan Jiang, and Siyang Yan, and Rong Fu
June 2018, Immunologic research,
Qing Shao, and Ling Deng, and Hui Liu, and Zhaoyun Liu, and Jin Chen, and Fengjuan Jiang, and Siyang Yan, and Rong Fu
September 2022, Molecular pharmaceutics,
Qing Shao, and Ling Deng, and Hui Liu, and Zhaoyun Liu, and Jin Chen, and Fengjuan Jiang, and Siyang Yan, and Rong Fu
November 2017, Journal of immunology (Baltimore, Md. : 1950),
Qing Shao, and Ling Deng, and Hui Liu, and Zhaoyun Liu, and Jin Chen, and Fengjuan Jiang, and Siyang Yan, and Rong Fu
March 1973, Nature,
Qing Shao, and Ling Deng, and Hui Liu, and Zhaoyun Liu, and Jin Chen, and Fengjuan Jiang, and Siyang Yan, and Rong Fu
May 2015, Oncotarget,
Copied contents to your clipboard!